Company intelligence / Profile preview

NeoVascularX, Inc.

Ownership: Private
Development stage: Preclinical

Overview

NeoVascularX is developing topical products for nAMD, which would be a significant advancement as currently all FDA-approved interventions are injections to the eye. Their approach aims to inhibit neovascularization in the back of the eye to improve symptoms of nAMD.

Therapeutic areas: Ophthalmology
Modalities: Topical ophthalmic products
Industry: Biotech

Drug pipeline

3 assets

NVX103

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NeoVascularX, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoVascularX, Inc..

Explore the full profile